Pipeline Drugs for COVID-19

The strange coronavirus flare-up in the Chinese city Wuhan, presently named as COVID-19, and its quick spread to numerous different nations, imperils a great many lives. The pandemic has catalyzed the advancement of novel coronavirus antibodies over the biotech business, both by pharmaceutical organizations and research associations, for example, the National Institutes of Health (NIH), US. 

The first COVID-19 immunization in China is relied upon to be prepared for clinical preliminaries before the finish of April, as indicated by Xu Nanping, China's bad habit priest of science and innovation. Inovio Pharmaceuticals intends to start clinical preliminaries on a coronavirus immunization in April this year. 

Wellbeing authorities from WHO have noticed that Gilead's remdesivir has exhibited viability in treating the coronavirus contamination.

Chloroquine to be tried for coronavirus treatment in the US 

The President of the United States, Donald Trump, declared on 19 March that chloroquine (hydroxychloroquine/Plaquenil), a medication used to treat jungle fever and joint pain, was endorsed by the US Food and Drug Administration (FDA) to be tried as a treatment for COVID-19. Chloroquine is being tried in different clinical preliminaries directed by government offices and scholastic establishments. 

Different antivirals drugs are likewise wanted to be optimized for testing for coronavirus. 

Favilavir, the primary endorsed coronavirus sedate in China 

The National Medical Products Administration of China has endorsed the utilization of Favilavir, an enemy of viral medication, as a treatment for coronavirus. The medication has supposedly indicated adequacy in treating the ailment with negligible reactions in a clinical preliminary including 70 patients. The clinical preliminary is being led in Shenzhen, Guangdong area. 

Pharmaceutical organizations engaged with creating coronavirus drugs/antibodies 

Here is a rundown of the major coronavirus drugs that pharmaceutical organizations over the world are building up that can possibly become major coronavirus immunizations or antivirals for treating the infectious coronavirus disease. 

Novel coronavirus antibodies 

Recorded underneath are the coronavirus immunizations in different phases of improvement, over the world. 

TJM2 by I-Mab Biopharma 

I-Mab Biopharma is created TJM2, a killing counter acting agent, as a treatment for cytokine storm in patients experiencing a serious instance of coronavirus disease. The medication focuses on the human granulocyte-macrophage province animating component (GM-CSF), which is answerable for intense and interminable irritation. 

The organization will start improvement in the wake of getting endorsement for the Investigational New Drug (IND) application from the U.S. Nourishment and Drug Administration (FDA). 

Coronavirus antibody by Medicago 

Medicago is creating drug applicants against COVID-19 subsequent to having delivered Virus-Like Particles (VLP) of the coronavirus. The organization has shaped a joint effort with Laval University's Infectious Disease Research Center to create antibodies against SARS-CoV-2. 

The organization's examination exercises are as a rule somewhat subsidized by the Canadian Institutes for Health Research (CIHR). 

AT-100 via Airway Therapeutics 

Aviation route Therapeutics is investigating its novel human recombinant protein named AT-100 (rhSP-D) as a treatment for coronavirus. The organization has reported a documenting with the Respiratory Diseases Branch of the National Institutes of Health to assess the medication. 

AT-100 has demonstrated adequacy in preclinical investigations in decreasing irritation and contamination in the lungs, while likewise producing a safe reaction against different respiratory infections. 

TZLS-501 by Tiziana Life Sciences 

Tiziana Life Sciences is building up its monoclonal immune response named TZLS-501 for the treatment of COVID-19. TZLS-501 is a human enemy of interleukin-6 receptor (IL-6R), which helps in forestalling lung harm and raised degrees of IL-6. 

The medication works by authoritative to IL-6R and exhausting the measure of IL-6 flowing in the body in this way diminishing ceaseless lung irritation. 

OYA1 by OyaGen 

OyaGen's OYA1 has indicated solid antiviral viability against coronavirus in research facility papers. It was seen as more successful than chlorpromazine HCl in restraining SARS-CoV-2 from repeating in cell culture. 

BPI-002 by BeyondSpring 

BeyondSpring's BPI-002 is a little particle operator showed for treating different diseases including COVID-19. It can initiate CD4+ partner T cells and CD8+ cytotoxic T cells and creating an insusceptible reaction in the body. 

Altimmune's intranasal coronavirus antibody 

An intranasal Covid-19 antibody is being created by US-based clinical-organize biopharmaceutical organization, Altimmune. 

Plan and union of the single-portion immunization have been finished, while creature testing will follow. 

The coronavirus immunization is being created dependent on an antibody innovation stage that is like NasoVAX, a flu antibody created by Altimmune. 

INO-4800 by Inovio Pharmaceuticals and Beijing Advaccine Biotechnology 

Inovio Pharmaceuticals has teamed up with Beijing Advaccine Biotechnology Company to propel the advancement of the previous' antibody, INO-4800, as a novel coronavirus immunization. The organization has begun pre-clinical testing for clinical item fabricating. 

The immunization advancement is upheld by a $9m award from the Coalition for Epidemic Preparedness Innovations (CEPI). 

Inovio declared a quickened timetable for the advancement of the antibody on 03 March. Preclinical preliminaries are continuous and the structure for human clinical preliminaries have been finished. The organization has additionally arranged 3,000 portions for human clinical preliminaries wanted to be directed over the US, China, and South Korea. Plans for huge scope producing have likewise been created. 

Human clinical preliminaries in 30 solid volunteers are relied upon to initiate in April 2020 in the US, trailed by China, and South Korea. A stage one clinical preliminary is intended to be directed in equal in China, by Beijing Advaccine. Results from the clinical preliminaries are relied upon to be accessible in September 2020. 

Inovio means to create one million portions of the antibody before the finish of 2020 to play out extra clinical preliminaries or crisis use. 

NP-120 (Ifenprodil) by Algernon Pharmaceuticals 

Algernon Pharmaceuticals has reported that it is investigating its NP-120 (Ifenprodil) as a potential treatment COVID-19. Ifenprodil is a N-methyl-d-aspartate (NDMA) receptor glutamate receptor adversary sold under the brand name Cerocal. It has shown viability in improving survivability in mice contaminated with H5N1. 

APN01 by University of British Columbia and APEIRON Biologics 

A medication competitor created by APEIRON Biologics named APN01 is being tried in China in a stage one pilot preliminary as a treatment for COVID-19. APN01 depends on investigate directed by a teacher at the University of British Columbia for treating SARS. The exploration uncovered that the ACE2 protein was the principle receptor for the SARS infection. 

The clinical preliminary will test the medication's adequacy in lessening the viral burden in patients. Information from the preliminary will be utilized to decide whether extra clinical preliminaries are required to be led in bigger number of patients. 

mRNA-1273 immunization by Moderna and Vaccine Research Center 

Moderna and the Vaccine Research Center, a unit of the National Institute of Allergy and Infectious Diseases (NIAID), have teamed up to build up an antibody for coronavirus. The antibody focuses on the Spike (S) protein of the coronavirus. 

The main vials of the antibody have been made at Moderna's Massachusetts producing plant and transported to NIAID for stage one human clinical preliminary. The preliminary started on 16 March at the Kaiser Permanente Washington Health Research Institute in Seattle, Washington. An aggregate of 45 guys and females matured somewhere in the range of 18 and 45 have been enlisted for the preliminary. 

The members will be partitioned into three partners who will be directed 25 microgram (mcg), 100mcg or 250mcg portion 28 days separated. 

Avian Coronavirus Infectious Bronchitis Virus (IBV) antibody by MIGAL Research Institute 

The MIGAL Research Institute in Israel declared that an Infectious Bronchitis Virus (IBV) antibody created to treat avian coronavirus has been altered to treat COVID-19. The immunization has shown viability in pre-clinical preliminaries directed by the Volcani Institute. 

The IBV antibody was created following four years of research and has high hereditary likeness to the human coronavirus. The organization has hereditarily adjusted the antibody to treat COVID-19 and will be accessible in the oral structure. 

The organization is at present investigating potential accomplices for delivering the antibody in the following eight to ten weeks and getting the important security endorsements for in-vivo testing. 

TNX-1800 by Tonix Pharmaceuticals 

Tonix Pharmaceuticals has joined forces with Southern Research, a non-benefit inquire about association, to build up an immunization for coronavirus named TNX-1800. The antibody is a changed horsepox infection created utilizing Tonix's exclusive horsepox immunization stage. 

TNX-1800 is intended to communicate a protein got from the infection that causes the coronavirus disease. Southern Research will be liable for assessing the adequacy of the immunization, under the association. 

Brilacidin by Innovation Pharmaceuticals 

Development Pharmaceuticals reported that it is assessing Brilacidin, a defensin mimetic medication up-and-comer, as a potential treatment for coronavirus. Brilacidin has demonstrated antibacterial, mitigating and immunomodulatory properties in a few clinical preliminaries. 

The organization is wanting to investigate look into joint efforts and look for government awards to build up the coronavirus tranquilize. It is as of now exploring the medication for fiery gut illness and oral mucositis in malignant growth patients. 

Development has consented to two material exchange arrangements with a college in the US and 12 biocontainment labs in the US for assessment of Brilacidin as a treatment for COVID-19. One of the biocontainment labs is planned to begin testing of the medication in the third seven day stretch of March.

Share:

Read More

COVID 19 Treatment Challenge & Global Threat

The world is presently edgy to discover approaches to slow the spread of the novel coronavirus and to discover viable medications. As of Friday (March 20), 86 clinical preliminaries of COVID-19 medications or antibodies that are either continuous or enlisting patients. New ones are being included each day, as the case include in the U.S. (also, all around) skyrockets. The medications being tried range from repurposed influenza medicines to bombed ebola drugs, to intestinal sickness medicines that were first evolved decades prior. Here, we investigate a few of the medicines that specialists expectation will help battle COVID-19. 

Japan influenza Drug

A medication created by Fujifilm Toyama Chemical in Japan is indicating promising results in treating in any event mellow to direct instances of COVID-19, Live Science recently revealed. 

The antiviral medication, called Favipiravir or Avigan, has been utilized in Japan to treat flu, and a month ago, the medication was endorsed as an exploratory treatment for COVID-19 diseases, Pharmaceutical Technology announced. 

Up until this point, reports recommend the medication has been tried in 340 people in Wuhan and Shenzhen. "It has a high level of wellbeing and is obviously powerful in treatment," Zhang Xinmin, of China's science and innovation service, said March 17, The Guardian detailed. 

The medication, which works by forestalling certain infections from imitating, appeared to abbreviate the length of the infection just as improve lung conditions (as found in X-beams) in tried patients, however the examination presently can't seem to be distributed in a friend explored science diary. 

Chloroquine and hydroxychloroquine 

Chloroquine and hydroxychloroquine have been endorsed by the U.S. Nourishment and Drug Administration for the treatment of intestinal sickness, lupus and rheumatoid joint inflammation, yet fundamental research in human and primate cells proposes that the medications could adequately treat COVID-19. 

A recent report found that chloroquine could suppress the spread of SARS-CoV when applied to contaminated human cells in culture. SARS-CoV is firmly identified with the novel coronavirus, SARS-CoV-2, and caused a flare-up of serious intense respiratory disorder in 2002. Chloroquine upsets the capacity of the SARS-CoV infection to enter and duplicate in human cells, Live Science recently detailed. The cell culture investigations of SARS-CoV-2 uncovered that the medication and its subordinate hydroxychloroquine undermine the novel infection's replication likewise. 

Specialists in China, South Korea, France and the U.S. are currently giving the medication to certain patients with COVID-19 with promising, yet recounted, results up until this point. The FDA is sorting out a formal clinical preliminary of the medication. 

As of Feb. 23, seven clinical preliminaries had been enrolled in the Chinese Clinical Trial Registry to test whether COVID-19 contaminations could be treated with hydroxychloroquine. Also, the University of Minnesota is considering in the case of taking hydroxychloroquine can secure individuals living with contaminated COVID-19 patients from coming down with the infection themselves. 

In one intensely referenced investigation, led in France, few patients with COVID-19 got either hydroxychloroquine alone or hydroxychloroquine in mix with an anti-microbial called azithromycin. The creators detailed that perceivable groupings of SARS-CoV-2 fell altogether quicker in the examination members than coronavirus patients at other French clinics who didn't get either tranquilize. In six patients additionally given azithromycin, this promising impact had all the earmarks of being intensified. 

In any case, the CDC noticed that the little, non-randomized investigation "didn't evaluate clinical benefit[s]" related with the treatment; as it were, the examination didn't test whether the treated patients were bound to recuperate and endure their sickness. Moreover, the organization prompted that specialists ought to be careful when giving either medication to patients with ceaseless illness, for example, kidney disappointment, and particularly those "who are accepting drugs that may cooperate to cause arrhythmias." 

A bombed Ebola sedate 

A Gilead Sciences tranquilize that was initially tried in individuals with Ebola, remdesivir, is being repurposed to check whether it can successfully treat COVID-19. 

The medication was seen not as compelling in Ebola, yet in lab examines, it has demonstrated powerful at repressing the development of comparable infections, extreme intense respiratory disorder (SARS) and Middle East respiratory disorder (MERS). In a petri dish, remdesivir can keep human cells from getting contaminated with SARS-CoV-2, as indicated by a letter distributed in the diary Nature in February. 

The Food and Drug Administration has as of now endorsed utilization of remdesivir for humane use, which means just patients with serious COVID-19 infection can be affirmed for treatment. In different nations, prerequisites to get remdesivir might be less stringent. 

Five clinical preliminaries in China and the U.S. are as of now assessing whether remdesevir can lessen intricacies or abbreviate the illness course in COVID-19 patients, the clinical news site STAT detailed. 

Numerous specialists are amped up for the medication's latent capacity. 

"There's just one medication right since we think may have genuine viability," Bruce Aylward of the World Health Organization said a month ago, as detailed by STAT. "Also, that is remdesivir." 

George Thompson, an irresistible illness authority at UC Davis Medical Center who treated an early, serious instance of COVID-19, revealed to Science magazine that their patient showed signs of improvement in the wake of getting the medication, around 36 hours after conclusion. The specialists at first idea the patient would bite the dust, Thompson said. 

In any case, such episodic proof can't exhibit viability, and the lab still can't seem to dissect blood tests to show that the patient's clinical improvement following the organization of remdesivir corresponded with a drop in viral burden (grouping of viral particles). On the other side, an examination presented on the preprint database medRXiv took a gander at three patients treated with remdesivir. The investigation, which was not peer-audited, found no reasonable time-subordinate connection between getting the medication and seeing upgrades in manifestations. The patients additionally experienced rectal dying, raised liver catalysts, regurgitating and queasiness, which might be attached to the medication. 

Another situation is that antiviral medications by and large work better the prior patients get them, but since remdesivir isn't FDA-endorsed for general use, just patients with the most extreme, and late-arrange, infection, fit the bill for its utilization in clinical preliminaries, Thompson told Science. 

On Sunday (March 22), Gilead Sciences declared that they were incidentally stopping empathetic utilization of remdesivir, because of "overpowering interest." Instead, they are concentrating on favoring recently submitted demands and streamlining the procedure, while guiding individuals to try out clinical preliminaries, STAT detailed. 

A HIV Drug mix 

The antiviral medication kaletra, a mix of lopinavir and ritonavir, produced early energy. In any case, new information from China, distributed March 18 in the New England Journal of Medicine, couldn't identify an advantage when patients took the medication. 

An aggregate of 199 individuals with low oxygen levels were randomized to either get kaletra or a fake treatment. While less individuals taking kaletra kicked the bucket, the thing that matters was not measurably noteworthy, which means it could have been because of irregular possibility. Also, the two gatherings had comparable degrees of infection in their blood after some time. 

Nonetheless, different investigations are as yet progressing, there's as yet a chance this mix could give some profit. Similarly as with different antivirals, this medication would almost certainly work better whenever given before in the malady course. 

An immunosuppressant and a joint inflammation tranquilize 

Promotion 

For certain patients with COVID-19, the infection itself doesn't do the most noticeably terrible harm. Or maybe, in certain individuals their invulnerable framework goes into overdrive and jump starts a hard and fast attack known as a cytokine storm. That insusceptible overcompensation can harm tissue and at last slaughter individuals. 

To calm such cytokine storms, specialists are presently trying an immunosuppressant known as Actemra, or tocilizumab. The medication is affirmed to treat rheumatoid joint inflammation and adolescent rheumatoid joint pain. It hinders a phone receptor that ties something many refer to as interleukin 6 (IL-6). IL-6 is a cytokine, or a kind of protein discharged by the safe framework, that can trigger perilous provocative falls. 

On March 19, pharmaceutical organization Roche declared that it was propelling a preliminary to check whether tocilizumab could improve results in patients with COVID-19 pneumonia. One gathering will get the medication in addition to other standard medicines, while another gathering will get a fake treatment, in addition to standard medicines. 

Regeneron is enlisting patients in a clinical preliminary to test another IL-6 inhibitor, known as sarilumab (kevzara), for treating COVID-19 pneumonia. The rationale behind utilizing sarilumab is like that for tocilizumab. 

A Cardiovascular medicate 

Losartan is a nonexclusive pulse medicine that a few researchers are trusting could assist patients with COVID-19. The University of Minnesota has propelled two clinical preliminaries utilizing the economical, nonexclusive medication. The first would assess whether losartan can forestall multi-organ disappointment in those hospitalized with COVID-19 pneumonia. The second would assess if the medication can forestall hospitalizations in any case, Reuters revealed. 

Losartan works by obstructing a receptor, or entryway into cells that the concoction called angiotensin II uses to enter the phones and raise circulatory strain. SARS-CoV-2 ties to the angiotensin-changing over catalyst 2 (ACE2) receptor, and it's conceivable, the reasoning goes, that in light of the fact that losartan may obstruct those receptors, it might keep the infection from tainting cells. 

Share:

Read More

COVID19 Treatment with Hydroxychloroquine and Azithromycin

With the spread of the coronavirus over the world and expanding quantities of infected individuals, there's presently a universal race to create powerful medications for Covid-19. Hydroxychloroquine, a less-poisonous subsidiary of chloroquine has been identified acts against Viral load combined treatment with Azithromycin - macrolide group of antibiotic as to reduce infections can be treatment solution for COVID 19 infections.

But it has not been endorsed as a treatment for Covid-19, and at the present time, the proof for its adequacy is inadequate.

Chinese specialists appeared in lab cell culture tests that Hydroxychloroquine can slow diseases from the infection behind Covid-19, SARS-CoV-2, blocking it from entering cells. A few specialists in China and South Korea have additionally utilized it to treat patients. Furthermore, an ongoing report by specialists in France found that the medication was "productive" in clearing upper aviation routes from the infection in three to six days in many patients. That planning is significant on the grounds that an untreated contaminated individual can transmit the infection for 20 days or increasingly, even without demonstrating side effects. So it's imperative to recoil the measure of time an individual conveys the infection so as to restrain its spread.

"Such outcomes are promising and open the chance of a universal procedure to decision makers to battle this rising viral contamination continuously regardless of whether different systems and research including antibody improvement could be likewise compelling, yet just later on," the French scientists composed. "We in this way prescribe COVID-19 patients be treated with hydroxychloroquine and azithromycin to fix their disease and to restrict the transmission of the infection to others so as to control the spread of COVID-19 on the planet."

In any case, the scientists just took a gander at 36 patients and just 26 really got hydroxychloroquine in the examination — a little example size. Hydroxychloroquine can likewise have symptoms like migraines, wooziness, and the runs, so it's not something that specialists can blanketly recommend. Furthermore, the examination wasn't blinded, which means the patients comprehended what they were getting, nor was it randomized. That restricts the logical value of the examination. All things considered, there are plans for more extensive testing.

At this moment, the best method to battle the infection remains not getting tainted in any case, which means utilizing great individual cleanliness like hand washing and refrain from social gathering measures.

Precautions you can take

There are established precautions as below that you can take: 

• Practice good hand hygiene – wash your hands regularly with alcohol based hand rub or soap and water for at least 20 seconds, particularly after going to the toilet and before eating food;
• Practice good cough/sneeze etiquette – Cover your nose and mouth with a tissue when coughing or sneezing or cough or sneeze into the crook of your elbow, and encourage others to do the same. Dispose of tissues immediately and wash your hands afterwards;
• Avoid touching your eyes, nose and mouth with unclean hands;
• Stay at home if you are sick; Where possible, keep one metre away from people who have a respiratory illness; and
• Practicing social distancing and avoiding large public gatherings.

We all have an ethical responsibility to take all available measure to slow the spread of COVID-19

Share:

Read More

প্রতিদিন দুটো করে খেজুর খান আর দেখুন আপনার স্বাস্থ্যের কি উন্নতি হয় !

খেজুর একটি স্বাস্থ্যকর খাবার,  ফলটির অজস্র অনস্বীকার্য উপকারিতা রয়েছে, তাই  প্রতিদিন দুটো করে খেজুর খান আর দেখুন আপনার স্বাস্থ্যের কি উন্নতি হয়।

শরীরের শক্তির মাত্রা বাড়িয়ে দেয়

ক্রমাগত চাপ আর মস্তিষ্কের কাজের জন্য আমরা দুপুরের মধ্যে ক্লান্তি অনুভব করি। কিন্তু আপনি যদি সারাদিন আপনার শক্তি ধরে রাখতে চান আর দুপুরের মতো বিকেলেও যদি উৎপাদনশীল থাকতে চান তাহলে আপনার খাবারে খেজুর যোগ করুন। এই ফলটিতে প্রচুর পরিমানে প্রাকৃতিক চিনি যেমন: গ্লুকোজ, ফ্রুকটোজ এবং সুক্রোজ রয়েছে। আর এগুলো আপনার প্রয়োজনীয় শক্তি বৃদ্ধি করতে পারে বলে ইন্টারন্যাশনাল জার্নাল অব ফুড সায়েন্সেস এন্ড নিউট্রিশন এ প্রকশিত এক নিবন্ধে দেখা গেছে। গবেষণাটিতে দেখা গেছে পরিশ্রান্তির সময় কয়েকটি খেজুর চিবুলে তখুনি শরীরে শক্তির মাত্রা বেড়ে যায়। যখনই আপনি শ্রান্তি অনুভব করবেন তখনই এই কৌশলটি অবলম্বন করবেন।

কোলস্টেরলের মাত্রা কমায়

আপনার কোলস্টেরলের মাত্রা কমে যাবে যদিও খেজুর খুব মিষ্টি কিন্তু ওগুলোতে খুব কম স্নেহ পদার্থ রয়েছে। নিয়মিত খেজুর খেলে আপনার কোলস্টেরলের মাত্রায় ভারসাম্য থাকবে আর এগুলো আপনার ওজন কমতে সাহায্য করবে। উঁচু কোলস্টেরল শুধু আপনার শরীরের জন্য ক্ষতিকর নয় কোলস্টেরল হৃদরোগ এবং স্ট্রোকের ঝুঁকি বাড়ায়। দিনে দুটি খেজুর খেয়ে আপনি শুধুমাত্র আপনার শরীরের দেখভাল ই করবেন না বরং ভিতর থেকে শরীরকে রক্ষা করবেন।

পরিপাকতন্ত্র উন্নত করে

আপনার পরিপাকতন্ত্র আরো কার্যকর হবে। পরিপাকতন্ত্র আমাদের শরীরের অন্যতম গুরুত্বপূর্ণ অংশ আর এটি আমাদের সর্বোপরি স্বাস্থ্য তৈরি করতে পারে আর এতে সামান্য খুঁত থাকলে শরীর ভেঙ্গে যেতে পারে। খেজুর মুহূর্তের মধ্যে আপনার পরিপাকতন্ত্র ঠিক করতে পারে। খেজুরে দ্রবণযোগ্য আঁশ থাকে যা পরিপাকতন্ত্র নিয়ন্ত্রণের জন্য অত্যন্ত ভালো আর ওগুলো কোষ্ঠকাঠিন্যে সাহায্য করে। বিশেষজ্ঞরা কিছু খেজুর রাতভর ভিজিয়ে রেখে সকালে ওগুলো খাওয়ার নির্দেশ দেন যা খেজুরের প্রাকৃতিক স্বক্ষমতা বাড়িয়ে দেয় আর আপনার পরিপাকতন্ত্রকে ভালোভাবে কাজ করতে সাহায্য করে।

রক্তচাপ নিয়ন্ত্রণ করে

খাবারের সঙ্গে আমরা যে অতিরিক্ত সোডিয়াম ও লবন খাই কখনো কখনো তার ফল হলো উচ্চ রক্তচাপ। খেজুরে কোন সোডিয়াম থাকে না বরং ওগুলোতে প্রচুর পরিমানে পটাসিয়াম থাকে যা সোডিয়াম শরীর থেকে বের করে দিতে সাহায্য করে। এজন্য খেজুর রক্তচাপ নিয়ন্ত্রণে এতো ভালো কাজ করে। এজন্য আপনার যদি উচ্চ রক্তচাপের সমস্যা থাকে আর আপনি যদি অধিক প্রাকৃতিক সমাধান খুঁজতে থাকেন তাহলে ফলটির দিকে বেশি মনোযোগ দিন।

দৃষ্টিশক্তি উন্নত করে

পরিপূর্ণ চোখের দৃষ্টিসহ কাউকে খুঁজে পাওয়া কঠিন। কম্পিউটার ও ফোনের স্ক্রিনে কাজ বা পড়ালেখা করার কারণে আমাদের চোখের স্বাস্থ্য আক্রান্ত হয়। সৌভাগ্যবশত অনেকগুলো প্রাকৃতিক এবং স্বাস্থ্যকর খাবার আছে যা আমাদের সাহায্য করতে পারে আর খেজুর ওগুলোর মধ্যে অন্যতম। এই ফলটি বেশি মাত্রায় ভিটামিন এ থাকে যা আপনার চোখে যথোপযুক্ত মাত্রার পুষ্টি যোগায়। আর এতে আপনার দৃষ্টিশক্তি শক্তিশালী হয়। সুতরাং দৃষ্টিশক্তি খারাপ হওয়া যদি আপনার সবচেয়ে বড় সমস্যা হয় বা সমস্যাটি যদি সহনযোগ্য মাত্রার হয় তাহলে খেজুর আপনার চোখের অবস্থা অনেক ভালো করতে পারবে।

হাঁড়ের যত্ন নেয়

এটি কোন গোপন বিষয় নয় যে আমরা যতো বৃদ্ধ হই আমাদের হাঁড় ততো ভঙ্গুর হয়ে যায় আর এই সমস্যাগুলো সহজে ভালো হয় না। এতে প্রচন্ড ব্যাথা হয় শরীরে। শরীরে বিকলঙ্গতার সৃষ্টি হওয়াসহ অনেক অপ্রীতিকর ব্যাপার ঘটতে পারে। খেজুরে প্রচুর পরিমানে ফসফরাস, পটাসিয়াম, ক্যালসিয়াম এবং ম্যাগনেসিয়াম আছে। এই খনিজগুলো অস্টিওপেরোসিসসহ হাঁড়ের রোগগুলো ভালো করার ব্যাপারে সুপরিচিত। এজন্য, আপনি যদি আপনার হাঁড়কে অতিরিক্ত কিছু দিতে চান তাহলে খেজুর খাওয়া একটি ভালো কৌশল হিসেবে পরিগণিত হবে।

Share:

Read More